CI-994 is a histone deacetylase (HDAC) inhibitor that induces histone hyperacetylation. CI-994 inhibited HDAC-1 and HDAC-2 but not GCN5. CI-994 is also a novel antitumor agent, exhibiting activity against pancreatic, colon and mammary tumors. CI-994 inhibited the growth of two non-small cell lung cancer cell lines, A-549 (adenocarcinoma) and LX-1 (squamous cell carcinoma), with an IC50 of 80 µM.

Acetyldinaline, Gö 5549, PD 123654, Tacedinaline

≥99%

Soluble in DMSO at 66 mg/ml; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 25-100 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.

White to off-white powder

Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.

1. Kraker, A.J., et al. Mol. Cancer Ther. 2: 401-408 (2003).
2. LoRusso, P.M., et al. Invest. New Drugs 14: 349-356 (1996).
3. Loprevite, M., et al. Oncol. Res. 15: 39-48 (2005).

HDAC

Inhibitor